[How to approach follow-up of uveitis patients during the Covid-19 pandemic?]
Identifieur interne : 000162 ( Main/Exploration ); précédent : 000161; suivant : 000163[How to approach follow-up of uveitis patients during the Covid-19 pandemic?]
Auteurs : S. Touhami [France] ; D. Saadoun [France] ; L. Kodjikian [France] ; B. Bodaghi [France]Source :
- Journal francais d'ophtalmologie [ 1773-0597 ] ; 2020.
Descripteurs français
- KwdFr :
- Abstention thérapeutique (normes), Antiviraux (usage thérapeutique), Betacoronavirus (MeSH), Hospitalisation (MeSH), Humains (MeSH), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (usage thérapeutique), Infections à coronavirus (diagnostic), Infections à coronavirus (prévention et contrôle), Infections à coronavirus (épidémiologie), Injections intravitréennes (MeSH), Pandémies (prévention et contrôle), Pneumopathie virale (diagnostic), Pneumopathie virale (prévention et contrôle), Pneumopathie virale (épidémiologie), Récidive (MeSH), Sclérite (traitement médicamenteux), Soins ambulatoires (méthodes), Stéroïdes (administration et posologie), Stéroïdes (usage thérapeutique), Télémédecine (MeSH), Uvéite (diagnostic), Uvéite (traitement médicamenteux), Uvéite (étiologie), Uvéite antérieure (traitement médicamenteux).
- MESH :
- administration et posologie : Immunosuppresseurs, Stéroïdes.
- diagnostic : Infections à coronavirus, Pneumopathie virale, Uvéite.
- méthodes : Soins ambulatoires.
- normes : Abstention thérapeutique.
- prévention et contrôle : Infections à coronavirus, Pandémies, Pneumopathie virale.
- traitement médicamenteux : Sclérite, Uvéite, Uvéite antérieure.
- usage thérapeutique : Antiviraux, Immunosuppresseurs, Stéroïdes.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- étiologie : Uvéite.
- Betacoronavirus, Hospitalisation, Humains, Injections intravitréennes, Récidive, Télémédecine.
English descriptors
- KwdEn :
- Ambulatory Care (methods), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), Coronavirus Infections (diagnosis), Coronavirus Infections (epidemiology), Coronavirus Infections (prevention & control), Hospitalization (MeSH), Humans (MeSH), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (therapeutic use), Intravitreal Injections (MeSH), Pandemics (prevention & control), Pneumonia, Viral (diagnosis), Pneumonia, Viral (epidemiology), Pneumonia, Viral (prevention & control), Recurrence (MeSH), Scleritis (drug therapy), Steroids (administration & dosage), Steroids (therapeutic use), Telemedicine (MeSH), Uveitis (diagnosis), Uveitis (drug therapy), Uveitis (etiology), Uveitis, Anterior (drug therapy), Withholding Treatment (standards).
- MESH :
- chemical , administration & dosage : Immunosuppressive Agents, Steroids.
- chemical , therapeutic use : Antiviral Agents, Immunosuppressive Agents, Steroids.
- diagnosis : Coronavirus Infections, Pneumonia, Viral, Uveitis.
- drug therapy : Scleritis, Uveitis, Uveitis, Anterior.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- etiology : Uveitis.
- methods : Ambulatory Care.
- prevention & control : Coronavirus Infections, Pandemics, Pneumonia, Viral.
- standards : Withholding Treatment.
- Betacoronavirus, Hospitalization, Humans, Intravitreal Injections, Recurrence, Telemedicine.
DOI: 10.1016/j.jfo.2020.04.012
PubMed: 32386902
PubMed Central: PMC7190488
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[How to approach follow-up of uveitis patients during the Covid-19 pandemic?]</title><author><name sortKey="Touhami, S" sort="Touhami, S" uniqKey="Touhami S" first="S" last="Touhami">S. Touhami</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Saadoun, D" sort="Saadoun, D" uniqKey="Saadoun D" first="D" last="Saadoun">D. Saadoun</name><affiliation wicri:level="3"><nlm:affiliation>Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kodjikian, L" sort="Kodjikian, L" uniqKey="Kodjikian L" first="L" last="Kodjikian">L. Kodjikian</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: kodjikian.laurent@wanadoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bodaghi, B" sort="Bodaghi, B" uniqKey="Bodaghi B" first="B" last="Bodaghi">B. Bodaghi</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32386902</idno><idno type="pmid">32386902</idno><idno type="doi">10.1016/j.jfo.2020.04.012</idno><idno type="pmc">PMC7190488</idno><idno type="wicri:Area/Main/Corpus">001388</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001388</idno><idno type="wicri:Area/Main/Curation">001388</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001388</idno><idno type="wicri:Area/Main/Exploration">001388</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[How to approach follow-up of uveitis patients during the Covid-19 pandemic?]</title><author><name sortKey="Touhami, S" sort="Touhami, S" uniqKey="Touhami S" first="S" last="Touhami">S. Touhami</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Saadoun, D" sort="Saadoun, D" uniqKey="Saadoun D" first="D" last="Saadoun">D. Saadoun</name><affiliation wicri:level="3"><nlm:affiliation>Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Kodjikian, L" sort="Kodjikian, L" uniqKey="Kodjikian L" first="L" last="Kodjikian">L. Kodjikian</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: kodjikian.laurent@wanadoo.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bodaghi, B" sort="Bodaghi, B" uniqKey="Bodaghi B" first="B" last="Bodaghi">B. Bodaghi</name><affiliation wicri:level="3"><nlm:affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author></analytic><series><title level="j">Journal francais d'ophtalmologie</title><idno type="eISSN">1773-0597</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ambulatory Care (methods)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>Coronavirus Infections (diagnosis)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (prevention & control)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Intravitreal Injections (MeSH)</term><term>Pandemics (prevention & control)</term><term>Pneumonia, Viral (diagnosis)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (prevention & control)</term><term>Recurrence (MeSH)</term><term>Scleritis (drug therapy)</term><term>Steroids (administration & dosage)</term><term>Steroids (therapeutic use)</term><term>Telemedicine (MeSH)</term><term>Uveitis (diagnosis)</term><term>Uveitis (drug therapy)</term><term>Uveitis (etiology)</term><term>Uveitis, Anterior (drug therapy)</term><term>Withholding Treatment (standards)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Abstention thérapeutique (normes)</term><term>Antiviraux (usage thérapeutique)</term><term>Betacoronavirus (MeSH)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (administration et posologie)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Infections à coronavirus (diagnostic)</term><term>Infections à coronavirus (prévention et contrôle)</term><term>Infections à coronavirus (épidémiologie)</term><term>Injections intravitréennes (MeSH)</term><term>Pandémies (prévention et contrôle)</term><term>Pneumopathie virale (diagnostic)</term><term>Pneumopathie virale (prévention et contrôle)</term><term>Pneumopathie virale (épidémiologie)</term><term>Récidive (MeSH)</term><term>Sclérite (traitement médicamenteux)</term><term>Soins ambulatoires (méthodes)</term><term>Stéroïdes (administration et posologie)</term><term>Stéroïdes (usage thérapeutique)</term><term>Télémédecine (MeSH)</term><term>Uvéite (diagnostic)</term><term>Uvéite (traitement médicamenteux)</term><term>Uvéite (étiologie)</term><term>Uvéite antérieure (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunosuppressive Agents</term><term>Steroids</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Immunosuppressive Agents</term><term>Steroids</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term><term>Stéroïdes</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term><term>Uveitis</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term><term>Uvéite</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Scleritis</term><term>Uveitis</term><term>Uveitis, Anterior</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Uveitis</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Ambulatory Care</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Soins ambulatoires</term></keywords><keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Abstention thérapeutique</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Coronavirus Infections</term><term>Pandemics</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Infections à coronavirus</term><term>Pandémies</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="standards" xml:lang="en"><term>Withholding Treatment</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Sclérite</term><term>Uvéite</term><term>Uvéite antérieure</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term><term>Immunosuppresseurs</term><term>Stéroïdes</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Uvéite</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>Hospitalization</term><term>Humans</term><term>Intravitreal Injections</term><term>Recurrence</term><term>Telemedicine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term><term>Hospitalisation</term><term>Humains</term><term>Injections intravitréennes</term><term>Récidive</term><term>Télémédecine</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32386902</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1773-0597</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal francais d'ophtalmologie</Title><ISOAbbreviation>J Fr Ophtalmol</ISOAbbreviation></Journal><ArticleTitle>[How to approach follow-up of uveitis patients during the Covid-19 pandemic?]</ArticleTitle><Pagination><MedlinePgn>535-536</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0181-5512(20)30176-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jfo.2020.04.012</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Touhami</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saadoun</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Service de médecine interne, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodjikian</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Service d'ophtalmologie, CHU Croix-Rousse, 103, grande rue de la Croix-Rousse, 69004 Lyon, France. Electronic address: kodjikian.laurent@wanadoo.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bodaghi</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Service d'ophtalmologie, CHU Pitié-Salpetrière, 47-83, boulevard de l'Hôpital, 75013 Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList><VernacularTitle>Conduite à tenir pour le suivi des patients atteints d’uvéite au cours de la pandémie Covid-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>J Fr Ophtalmol</MedlineTA><NlmUniqueID>7804128</NlmUniqueID><ISSNLinking>0181-5512</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013256">Steroids</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015423" MajorTopicYN="N">Scleritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013256" MajorTopicYN="N">Steroids</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014605" MajorTopicYN="N">Uveitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014606" MajorTopicYN="N">Uveitis, Anterior</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028761" MajorTopicYN="N">Withholding Treatment</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>04</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32386902</ArticleId><ArticleId IdType="pii">S0181-5512(20)30176-5</ArticleId><ArticleId IdType="doi">10.1016/j.jfo.2020.04.012</ArticleId><ArticleId IdType="pmc">PMC7190488</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li><li>Île-de-France</li></region><settlement><li>Lyon</li><li>Paris</li></settlement></list><tree><country name="France"><region name="Île-de-France"><name sortKey="Touhami, S" sort="Touhami, S" uniqKey="Touhami S" first="S" last="Touhami">S. Touhami</name></region><name sortKey="Bodaghi, B" sort="Bodaghi, B" uniqKey="Bodaghi B" first="B" last="Bodaghi">B. Bodaghi</name><name sortKey="Kodjikian, L" sort="Kodjikian, L" uniqKey="Kodjikian L" first="L" last="Kodjikian">L. Kodjikian</name><name sortKey="Saadoun, D" sort="Saadoun, D" uniqKey="Saadoun D" first="D" last="Saadoun">D. Saadoun</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000162 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000162 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32386902
|texte= [How to approach follow-up of uveitis patients during the Covid-19 pandemic?]
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32386902" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |